Top brand choice
Strength | Pack Size | Qty | |
---|---|---|---|
Strength
75mg
|
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Braftovi is a kinase inhibitor prescribed for treating certain forms of advanced cancers, notably unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. It is also prescribed for the treatment of metastatic colorectal cancer with a BRAF V600E mutation.
These genetic markers must be confirmed with an FDA-approved test before starting treatment. Braftovi works by blocking abnormal signals in cancer cells that promote uncontrolled growth.
Fact Table | |
---|---|
Formula | C22H27ClFN7O4 |
License | FDA approved |
Bioavailability | Approximately 86% |
Legal status | Prescription only |
Chemical Name | Methyl N-{(2S)-1-[4-(4-chloro-3-fluorophenyl)ureido]propan-2-yl}pyrazolo[1,5-a]pyrimidine-3-carboxylate |
Elimination half-life | Approximately 6 hours |
Dosage (Strength) | 75 mg, 150 mg capsules |
Pregnancy | Not recommended; consult a healthcare provider |
Brands | Braftovi |
Protein binding | >99% |
PubChem CID | 56852136 |
MedlinePlus | a618056 |
ChEBI | 134859 |
ATC code | L01EC04 |
DrugBank | DB11722 |
KEGG | D10930 |
Routes of administration | Oral |
The dosage is 300 mg or 450 mg by mouth once daily, depending on the type cancer being treated.
The active ingredient in Braftovi is encorafenib.
Common drug-drug interactions may include:
Ask your doctor or pharmacist about all precautions that apply to you before starting this drug.
The most common side effects of this drug can include:
Braftovi [package insert]. Boulder, Colorado : Array BioPharma; February 2022.